GERN - Meet members of the 2021 IPO class: Biotechs - 2

With a list of 62 recent IPOs making entry to The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on our previous article on biotech stocks in the group, in this article, we discuss another four biotechs making their debut in The Russell 2000. Omega Therapeutics  With its pipeline still in the pre-clinical stage, Omega Therapeutics (NASDAQ:OMGA), focused on mRNA-based therapeutics, made its public debut in late July to gain more than 19% since then. The ~$126 million in gross proceeds from the IPO is aimed at financing the development of its lead Omega Epigenomic Controller (OEC) candidate, OTX-2002, as a treatment of hepatocellular carcinoma, CEO Mahesh Karande said early this month. RNA therapeutics has garnered the attention of big pharma in recent months. A few days ago, French vaccine giant Sanofi (NASDAQ:SNY) completed its $3 billion deal

For further details see:

Meet members of the 2021 IPO class: Biotechs - 2